Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Can MRI screen for CSF biomarkers in neurodegenerative disease?

McMillan CT, Avants B, Irwin DJ, Toledo JB, Wolk DA, Van Deerlin VM, Shaw LM, Trojanoswki JQ, Grossman M.

Neurology. 2013 Jan 8;80(2):132-8. doi: 10.1212/WNL.0b013e31827b9147. Epub 2012 Dec 26.

2.

CSF biomarkers in frontotemporal lobar degeneration with known pathology.

Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, Moore P, de Koning I, Clark CM, Rosso S, Trojanowski J, Lee VM, Grossman M.

Neurology. 2008 May 6;70(19 Pt 2):1827-35. doi: 10.1212/01.wnl.0000311445.21321.fc.

3.

Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms.

Irwin DJ, McMillan CT, Toledo JB, Arnold SE, Shaw LM, Wang LS, Van Deerlin V, Lee VM, Trojanowski JQ, Grossman M.

Arch Neurol. 2012 Aug;69(8):1018-25. doi: 10.1001/archneurol.2012.26.

4.

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.

Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT, Xie SX, Lee VM, Shaw LM, Trojanowski JQ.

Acta Neuropathol. 2012 Jul;124(1):23-35. doi: 10.1007/s00401-012-0983-7. Epub 2012 Apr 22.

5.

Cerebrospinal fluid biomarkers in Progranulin mutations carriers.

Carecchio M, Fenoglio C, Cortini F, Comi C, Benussi L, Ghidoni R, Borroni B, De Riz M, Serpente M, Cantoni C, Franceschi M, Albertini V, Monaco F, Rainero I, Binetti G, Padovani A, Bresolin N, Scarpini E, Galimberti D.

J Alzheimers Dis. 2011;27(4):781-90. doi: 10.3233/JAD-2011-111046.

PMID:
21891865
6.

Novel CSF biomarkers for frontotemporal lobar degenerations.

Hu WT, Chen-Plotkin A, Grossman M, Arnold SE, Clark CM, Shaw LM, McCluskey L, Elman L, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ.

Neurology. 2010 Dec 7;75(23):2079-86. doi: 10.1212/WNL.0b013e318200d78d. Epub 2010 Nov 3.

7.

The power of neuroimaging biomarkers for screening frontotemporal dementia.

McMillan CT, Avants BB, Cook P, Ungar L, Trojanowski JQ, Grossman M.

Hum Brain Mapp. 2014 Sep;35(9):4827-40. doi: 10.1002/hbm.22515. Epub 2014 Mar 31.

8.

Cerebrospinal fluid tau in frontotemporal lobar degeneration: clinical, neuroimaging, and prognostic correlates.

Borroni B, Cerini C, Archetti S, Premi E, Cosseddu M, Ferrari M, Bellelli G, Gasparotti R, Caimi L, Di Luca M, Padovani A.

J Alzheimers Dis. 2011;23(3):505-12. doi: 10.3233/JAD-2010-101407.

PMID:
21098973
9.

Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia.

Hu WT, McMillan C, Libon D, Leight S, Forman M, Lee VM, Trojanowski JQ, Grossman M.

Neurology. 2010 Aug 17;75(7):595-602. doi: 10.1212/WNL.0b013e3181ed9c52.

10.

Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease.

Fortea J, Vilaplana E, Alcolea D, Carmona-Iragui M, Sánchez-Saudinos MB, Sala I, Antón-Aguirre S, González S, Medrano S, Pegueroles J, Morenas E, Clarimón J, Blesa R, Lleó A; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2014 Aug;76(2):223-30. doi: 10.1002/ana.24186. Epub 2014 Jun 13.

PMID:
24852682
11.

CSF Alzheimer's disease-like pattern in corticobasal syndrome: evidence for a distinct disorder.

Borroni B, Premi E, Agosti C, Alberici A, Cerini C, Archetti S, Lanari A, Paghera B, Lucchini S, Caimi L, Padovani A.

J Neurol Neurosurg Psychiatry. 2011 Aug;82(8):834-8. doi: 10.1136/jnnp.2010.221853. Epub 2011 Feb 22.

PMID:
21345847
12.

White matter imaging contributes to the multimodal diagnosis of frontotemporal lobar degeneration.

McMillan CT, Brun C, Siddiqui S, Churgin M, Libon D, Yushkevich P, Zhang H, Boller A, Gee J, Grossman M.

Neurology. 2012 May 29;78(22):1761-8. doi: 10.1212/WNL.0b013e31825830bd. Epub 2012 May 16.

13.

Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.

Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S.

Arch Neurol. 2009 May;66(5):632-7. doi: 10.1001/archneurol.2009.59.

14.

Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP.

Hu WT, Watts K, Grossman M, Glass J, Lah JJ, Hales C, Shelnutt M, Van Deerlin V, Trojanowski JQ, Levey AI.

Neurology. 2013 Nov 26;81(22):1945-52. doi: 10.1212/01.wnl.0000436625.63650.27. Epub 2013 Oct 30.

15.

Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O.

JAMA Neurol. 2014 Oct;71(10):1282-9. doi: 10.1001/jamaneurol.2014.1358.

PMID:
25155658
16.

MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Jul 28;73(4):294-301. doi: 10.1212/WNL.0b013e3181af79fb.

17.

White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration.

McMillan CT, Irwin DJ, Avants BB, Powers J, Cook PA, Toledo JB, McCarty Wood E, Van Deerlin VM, Lee VM, Trojanowski JQ, Grossman M.

J Neurol Neurosurg Psychiatry. 2013 Sep;84(9):949-55. doi: 10.1136/jnnp-2012-304418. Epub 2013 Mar 9.

18.

MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Jul 28;73(4):287-93. doi: 10.1212/WNL.0b013e3181af79e5.

19.

Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects.

Verwey NA, Kester MI, van der Flier WM, Veerhuis R, Berkhof H, Twaalfhoven H, Blankenstein MA, Scheltens And P, Pijnenburg YA.

J Alzheimers Dis. 2010;20(2):445-52. doi: 10.3233/JAD-2010-1392.

PMID:
20164558
20.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk